Lipicard Technologies Limited-Product Pipeline Review-2015

Lipicard Technologies Limited-Product Pipeline Review-2015

  • Products Id :- GMDHC07045CDB
  • |
  • Pages: 58
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Lipicard Technologies Limited-Product Pipeline Review-2015


Global Markets Direct's, 'Lipicard Technologies Limited-Product Pipeline Review-2015', provides an overview of the Lipicard Technologies Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lipicard Technologies Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Lipicard Technologies Limited including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Lipicard Technologies Limited's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Lipicard Technologies Limited's pipeline products

Reasons To Buy

Evaluate Lipicard Technologies Limited's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Lipicard Technologies Limited in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Lipicard Technologies Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Lipicard Technologies Limited and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lipicard Technologies Limited

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Lipicard Technologies Limited and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Lipicard Technologies Limited Snapshot 7

Lipicard Technologies Limited Overview 7

Key Information 7

Key Facts 7

Lipicard Technologies Limited-Research and Development Overview 8

Key Therapeutic Areas 8

Lipicard Technologies Limited-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Lipicard Technologies Limited-Pipeline Products Glance 13

Lipicard Technologies Limited-Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 15

Lipicard Technologies Limited-Drug Profiles 16

Gabafol 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

KeraKlear 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

LT-1121 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

LT-1123 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

LT-2121 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

LT-2221 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

LT-2223 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

LT-2321 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

LT-2322 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

LT-2323 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

LT-2421 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

LT-2423 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

LT-2521 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

LT-3121 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

LT-3122 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

LT-4121 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

LT-4122 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

LT-4123 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

LT-4124 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

LT-4125 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

LT-4126 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

LT-5121 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

LT-5122 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

LT-5221 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

LT-5222 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

LT-5223 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

LT-5321 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

LT-5322 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

LT-5323 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

LT-5421 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

LT-5423 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

LT5521 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Peroxibrate 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Platrol 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Raviprofen 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

LT-6121 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Lipicard Technologies Limited-Pipeline Analysis 52

Lipicard Technologies Limited-Pipeline Products by Target 52

Lipicard Technologies Limited-Pipeline Products by Route of Administration 53

Lipicard Technologies Limited-Pipeline Products by Molecule Type 54

Lipicard Technologies Limited-Pipeline Products by Mechanism of Action 55

Lipicard Technologies Limited-Locations And Subsidiaries 56

Head Office 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

Lipicard Technologies Limited, Key Information 7

Lipicard Technologies Limited, Key Facts 7

Lipicard Technologies Limited-Pipeline by Indication, 2015 9

Lipicard Technologies Limited-Pipeline by Stage of Development, 2015 11

Lipicard Technologies Limited-Monotherapy Products in Pipeline, 2015 12

Lipicard Technologies Limited-Preclinical, 2015 13

Lipicard Technologies Limited-Discovery, 2015 15

Lipicard Technologies Limited-Pipeline by Target, 2015 52

Lipicard Technologies Limited-Pipeline by Route of Administration, 2015 53

Lipicard Technologies Limited-Pipeline by Molecule Type, 2015 54

Lipicard Technologies Limited-Pipeline Products by Mechanism of Action, 2015 55

List of Figures

Lipicard Technologies Limited-Pipeline by Top 10 Indication, 2015 9

Lipicard Technologies Limited-Pipeline by Stage of Development, 2015 11

Lipicard Technologies Limited-Monotherapy Products in Pipeline, 2015 12

Lipicard Technologies Limited-Pipeline by Top 10 Target, 2015 52

Lipicard Technologies Limited-Pipeline by Top 10 Route of Administration, 2015 53

Lipicard Technologies Limited-Pipeline by Top 10 Molecule Type, 2015 54

Lipicard Technologies Limited-Pipeline Products by Top 10 Mechanism of Action, 2015 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Lipicard Technologies Limited; Lipicard Technologies Limited - Key Therapeutics; Lipicard Technologies Limited - Pipeline Overview and Promising Molecules; Lipicard Technologies Limited - News; Lipicard Technologies Limited - Latest Updates; Lipicard Technologies Limited - Pipeline; Lipicard Technologies Limited - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101595
Site License
USD 3000 INR 203190
Corporate User License
USD 4500 INR 304785



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]